Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3651
Citizens Community Bancorp
CZWI
$200M
| $661K | ﹤0.01% |
37,077
+1,323
| +4% | +$22.2K |
|
3652
Forte Biosciences
FBRX
$1.57B
| $658K | ﹤0.01% |
24,111
+23,291
| +2,840% | +$408K |
|
3653
BCB Bancorp
BCBP
$162M
| $656K | ﹤0.01% |
81,340
+1,565
| +2% | +$12.6K |
|
3654
Kopin
KOPN
$914M
| $656K | ﹤0.01% |
280,287
+52,496
| +23% | +$152K |
|
3655
Definitive Healthcare
DH
$69.4M
| $655K | ﹤0.01% |
228,349
+177,938
| +353% | +$493K |
|
|
NMAX
3656
Newsmax Inc
NMAX
$1.16B
| $655K | ﹤0.01% |
84,775
+69,266
| +447% | +$665K |
|
3657
United States Natural Gas Fund
UNG
$491M
| $653K | ﹤0.01% |
53,271
-6,948
| -12% | -$93.5K |
|
3658
Nektar Therapeutics
NKTR
$2.59B
| $653K | ﹤0.01% |
15,444
-1,235
| -7% | -$69.1K |
|
|
ABX
3659
Abacus Global Management
ABX
$837M
| $652K | ﹤0.01% |
76,315
+5,951
| +8% | +$39.2K |
|
|
GRSD
3660
Grandstand Limited Ordinary Shares
GRSD
$66.3M
| $652K | ﹤0.01% |
119,396
+28,323
| +31% | +$180K |
|
3661
Jakks Pacific
JAKK
$294M
| $651K | ﹤0.01% |
38,571
+447
| +1% | +$7.74K |
|
3662
ClearPoint Neuro
CLPT
$465M
| $647K | ﹤0.01% |
47,313
+9,053
| +24% | +$168K |
|
3663
Northeast Community Bancorp
NECB
$373M
| $647K | ﹤0.01% |
28,601
+3,100
| +12% | +$65.5K |
|
3664
First United
FUNC
$297M
| $647K | ﹤0.01% |
17,269
+6,516
| +61% | +$242K |
|
3665
Thryv Holdings
THRY
$94.2M
| $645K | ﹤0.01% |
106,674
+49,335
| +86% | +$391K |
|
3666
GlobalFoundries
GFS
$29.3B
| $645K | ﹤0.01% |
18,459
-538,652
| -97% | -$19.2M |
|
3667
Mesa Laboratories
MLAB
$641M
| $643K | ﹤0.01% |
8,186
+523
| +7% | +$39.8K |
|
3668
Consensus Cloud Solutions
CCSI
$685M
| $640K | ﹤0.01% |
29,349
+2,027
| +7% | +$49.9K |
|
3669
Procore
PCOR
$8.79B
| $639K | ﹤0.01% |
8,786
-7,530
| -46% | -$557K |
|
3670
Voyager Therapeutics
VYGR
$198M
| $637K | ﹤0.01% |
162,112
+4,003
| +3% | +$17.7K |
|
3671
Blue Owl Capital
OBDC
$5.83B
| $637K | ﹤0.01% |
51,210
-93,148
| -65% | -$1.18M |
|
3672
Vanguard Information Technology ETF
VGT
$151B
| $636K | ﹤0.01% |
6,752
-567,288
| -99% | -$53.9M |
|
3673
Kodak
KODK
$996M
| $635K | ﹤0.01% |
75,025
-15,187
| -17% | -$114K |
|
3674
Greenlight Captial
GLRE
$509M
| $634K | ﹤0.01% |
43,458
+5,486
| +14% | +$72.1K |
|
3675
Frontier Group Holdings
ULCC
$1.58B
| $632K | ﹤0.01% |
134,284
-17,936
| -12% | -$79.5K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.